Diagnostic companies are on radar given the recent fresh price cap on COVID-19 testing. Om Manchanda, MD of Dr Lal Pathlabs, on Monday said that they will continue to support the government when it comes to testing but pointed out that eventually, the cuts will impact services.
Speaking further in an interview to CNBC-TV18, he said, “Given our scale and portfolio we are managing it now, but any further cut in prices will hurt the entire industry as well as the company.”
He believes there are misconceptions around the pricing of COVID testing.
“There is a general misconception that a kit cost is equal to the cost of doing a test,” he added.
According to him, the non-COVID portfolio is important for the business. “We should see the normal trajectory of non-COVID testing by Q4,” Manchanda said.
For entire interview, watch the video